- Title
- Results from a phase 2, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of VT 1161 oral tablets in the treatment of patients with recurrent vulvovaginal candidiasis
- Creators
- J.D. Sobel - Wayne State UniversityS.R. Brand - Viamet Pharmaceuticals (United States)T.P. Degenhardt - Viamet Pharmaceuticals (United States)K. Person - Viamet Pharmaceuticals (United States)P. Nyirjesy - Drexel UniversityR.J. Schotzinger - Viamet Pharmaceuticals (United States)A. Tavakkol - Viamet Pharmaceuticals (United States)
- Publication Details
- American journal of obstetrics and gynecology, v 217(6), pp 715-715
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Web of Science ID
- WOS:000416950700039
- Other Identifier
- 991019350683104721
Journal article
Results from a phase 2, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of VT 1161 oral tablets in the treatment of patients with recurrent vulvovaginal candidiasis
American journal of obstetrics and gynecology, v 217(6), pp 715-715
Dec 2017
Featured in Collection : UN Sustainable Development Goals @ Drexel
Metrics
2 Record Views
Details
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Obstetrics & Gynecology